| . | Preprotocol (n = 88) . | Protocol (n = 151) . | P Value . |
|---|---|---|---|
| Time to stent removal, d | 36 (32–40) | 25 (23–31) | <.001 |
| Stent removed while patient was hospitalized | 21 (23.9) | 32 (21.2) | .632 |
| Urinalysis within 30 d prior to stent removal | 65 (73.9) | 111 (73.5) | .302 |
| >20 WBCs | 10 (15.4) | 8 (7.2) | .087 |
| 10–20 WBCs | 24 (36.9) | 52 (46.8) | .251 |
| 0–5 WBCs | 31 (47.7) | 51 (45.9) | .820 |
| Urine culture within 30 d prior to stent removal | 40 (45.5) | 141 (94.4) | <.001 |
| Positive urine culture | 5 (12.5) | 20 (14.2) | .080 |
| Organisms growing in most recent urine culture prior to stent removala | |||
| Enterococcus spp | 3 (7.5) | 8 (5.7) | .751 |
| Escherichia coli | 1 (2.5) | 5 (3.5) | .418 |
| Gardnerella vaginalis | 0 | 3 (2.0) | .299 |
| Citrobacter spp | 1 (2.5) | 1 (0.7) | >.999 |
| Klebsiella spp (excluding K aerogenes) | 1 (2.5) | 0 | .368 |
| Pseudomonas spp | 0 | 1 (0.7) | >.999 |
| Morganella morganii | 0 | 1 (0.7) | >.999 |
| Candida glabrata | 0 | 1 (0.7) | >.999 |
| Other | 0 | 1 (0.7) | >.999 |
| No growth or mixed flora without specific organism identified | 35 (87.5) | 120 (85.1) | <.001 |
| Received antibiotics preprocedurea,b | 32 (36.4) | 150 (99.3) | <.001 |
| Cephalexin | 8 (25.0) | 114 (76.0) | <.001 |
| Cefazolin | 10 (31.3) | 14 (9.3) | .604 |
| Ciprofloxacin | 6 (18.9) | 7 (4.7) | .473 |
| Levofloxacin | 0 | 7 (4.7) | .049 |
| Cefdinir | 0 | 4 (2.7) | <.001 |
| Cefepime | 3 (9.4) | 4 (2.7) | .710 |
| Amoxicillin | 0 | 4 (2.7) | .161 |
| Vancomycin | 1 (3.1) | 4 (2.7) | .654 |
| Tobramycin | 0 | 4 (2.7) | .300 |
| Gentamicin | 3 (9.4) | 2 (1.3) | .360 |
| Otherc | 5 (15.6) | 7 (4.7) | .764 |
| TMP-SMX for prophylaxis at time of stent removald | 81 (92.0) | 135 (89.4) | .651 |
| Received antibiotics postprocedure | 10 (11) | 29 (19) | .148 |
| Duration of antibiotics postprocedure, d | 4 (2–15) | 4 (2–7) | … |
| . | Preprotocol (n = 88) . | Protocol (n = 151) . | P Value . |
|---|---|---|---|
| Time to stent removal, d | 36 (32–40) | 25 (23–31) | <.001 |
| Stent removed while patient was hospitalized | 21 (23.9) | 32 (21.2) | .632 |
| Urinalysis within 30 d prior to stent removal | 65 (73.9) | 111 (73.5) | .302 |
| >20 WBCs | 10 (15.4) | 8 (7.2) | .087 |
| 10–20 WBCs | 24 (36.9) | 52 (46.8) | .251 |
| 0–5 WBCs | 31 (47.7) | 51 (45.9) | .820 |
| Urine culture within 30 d prior to stent removal | 40 (45.5) | 141 (94.4) | <.001 |
| Positive urine culture | 5 (12.5) | 20 (14.2) | .080 |
| Organisms growing in most recent urine culture prior to stent removala | |||
| Enterococcus spp | 3 (7.5) | 8 (5.7) | .751 |
| Escherichia coli | 1 (2.5) | 5 (3.5) | .418 |
| Gardnerella vaginalis | 0 | 3 (2.0) | .299 |
| Citrobacter spp | 1 (2.5) | 1 (0.7) | >.999 |
| Klebsiella spp (excluding K aerogenes) | 1 (2.5) | 0 | .368 |
| Pseudomonas spp | 0 | 1 (0.7) | >.999 |
| Morganella morganii | 0 | 1 (0.7) | >.999 |
| Candida glabrata | 0 | 1 (0.7) | >.999 |
| Other | 0 | 1 (0.7) | >.999 |
| No growth or mixed flora without specific organism identified | 35 (87.5) | 120 (85.1) | <.001 |
| Received antibiotics preprocedurea,b | 32 (36.4) | 150 (99.3) | <.001 |
| Cephalexin | 8 (25.0) | 114 (76.0) | <.001 |
| Cefazolin | 10 (31.3) | 14 (9.3) | .604 |
| Ciprofloxacin | 6 (18.9) | 7 (4.7) | .473 |
| Levofloxacin | 0 | 7 (4.7) | .049 |
| Cefdinir | 0 | 4 (2.7) | <.001 |
| Cefepime | 3 (9.4) | 4 (2.7) | .710 |
| Amoxicillin | 0 | 4 (2.7) | .161 |
| Vancomycin | 1 (3.1) | 4 (2.7) | .654 |
| Tobramycin | 0 | 4 (2.7) | .300 |
| Gentamicin | 3 (9.4) | 2 (1.3) | .360 |
| Otherc | 5 (15.6) | 7 (4.7) | .764 |
| TMP-SMX for prophylaxis at time of stent removald | 81 (92.0) | 135 (89.4) | .651 |
| Received antibiotics postprocedure | 10 (11) | 29 (19) | .148 |
| Duration of antibiotics postprocedure, d | 4 (2–15) | 4 (2–7) | … |
Data are presented as median (IQR) or No. (%).
Abbreviations: TMP-SMX: trimethoprim-sulfamethoxazole; WBC, white blood cell.
aNot mutually exclusive.
bDoes not include TMP-SMX for prophylaxis.
cAmoxicillin-clavulanate, ampicillin, ceftazidime-avibactam, ceftriaxone, clindamycin, daptomycin, ertapenem, linezolid, meropenem, metronidazole, piperacillin-tazobactam.
dTMP-SMX dosed at 80–400 mg daily (renally adjusted as needed).
| . | Preprotocol (n = 88) . | Protocol (n = 151) . | P Value . |
|---|---|---|---|
| Time to stent removal, d | 36 (32–40) | 25 (23–31) | <.001 |
| Stent removed while patient was hospitalized | 21 (23.9) | 32 (21.2) | .632 |
| Urinalysis within 30 d prior to stent removal | 65 (73.9) | 111 (73.5) | .302 |
| >20 WBCs | 10 (15.4) | 8 (7.2) | .087 |
| 10–20 WBCs | 24 (36.9) | 52 (46.8) | .251 |
| 0–5 WBCs | 31 (47.7) | 51 (45.9) | .820 |
| Urine culture within 30 d prior to stent removal | 40 (45.5) | 141 (94.4) | <.001 |
| Positive urine culture | 5 (12.5) | 20 (14.2) | .080 |
| Organisms growing in most recent urine culture prior to stent removala | |||
| Enterococcus spp | 3 (7.5) | 8 (5.7) | .751 |
| Escherichia coli | 1 (2.5) | 5 (3.5) | .418 |
| Gardnerella vaginalis | 0 | 3 (2.0) | .299 |
| Citrobacter spp | 1 (2.5) | 1 (0.7) | >.999 |
| Klebsiella spp (excluding K aerogenes) | 1 (2.5) | 0 | .368 |
| Pseudomonas spp | 0 | 1 (0.7) | >.999 |
| Morganella morganii | 0 | 1 (0.7) | >.999 |
| Candida glabrata | 0 | 1 (0.7) | >.999 |
| Other | 0 | 1 (0.7) | >.999 |
| No growth or mixed flora without specific organism identified | 35 (87.5) | 120 (85.1) | <.001 |
| Received antibiotics preprocedurea,b | 32 (36.4) | 150 (99.3) | <.001 |
| Cephalexin | 8 (25.0) | 114 (76.0) | <.001 |
| Cefazolin | 10 (31.3) | 14 (9.3) | .604 |
| Ciprofloxacin | 6 (18.9) | 7 (4.7) | .473 |
| Levofloxacin | 0 | 7 (4.7) | .049 |
| Cefdinir | 0 | 4 (2.7) | <.001 |
| Cefepime | 3 (9.4) | 4 (2.7) | .710 |
| Amoxicillin | 0 | 4 (2.7) | .161 |
| Vancomycin | 1 (3.1) | 4 (2.7) | .654 |
| Tobramycin | 0 | 4 (2.7) | .300 |
| Gentamicin | 3 (9.4) | 2 (1.3) | .360 |
| Otherc | 5 (15.6) | 7 (4.7) | .764 |
| TMP-SMX for prophylaxis at time of stent removald | 81 (92.0) | 135 (89.4) | .651 |
| Received antibiotics postprocedure | 10 (11) | 29 (19) | .148 |
| Duration of antibiotics postprocedure, d | 4 (2–15) | 4 (2–7) | … |
| . | Preprotocol (n = 88) . | Protocol (n = 151) . | P Value . |
|---|---|---|---|
| Time to stent removal, d | 36 (32–40) | 25 (23–31) | <.001 |
| Stent removed while patient was hospitalized | 21 (23.9) | 32 (21.2) | .632 |
| Urinalysis within 30 d prior to stent removal | 65 (73.9) | 111 (73.5) | .302 |
| >20 WBCs | 10 (15.4) | 8 (7.2) | .087 |
| 10–20 WBCs | 24 (36.9) | 52 (46.8) | .251 |
| 0–5 WBCs | 31 (47.7) | 51 (45.9) | .820 |
| Urine culture within 30 d prior to stent removal | 40 (45.5) | 141 (94.4) | <.001 |
| Positive urine culture | 5 (12.5) | 20 (14.2) | .080 |
| Organisms growing in most recent urine culture prior to stent removala | |||
| Enterococcus spp | 3 (7.5) | 8 (5.7) | .751 |
| Escherichia coli | 1 (2.5) | 5 (3.5) | .418 |
| Gardnerella vaginalis | 0 | 3 (2.0) | .299 |
| Citrobacter spp | 1 (2.5) | 1 (0.7) | >.999 |
| Klebsiella spp (excluding K aerogenes) | 1 (2.5) | 0 | .368 |
| Pseudomonas spp | 0 | 1 (0.7) | >.999 |
| Morganella morganii | 0 | 1 (0.7) | >.999 |
| Candida glabrata | 0 | 1 (0.7) | >.999 |
| Other | 0 | 1 (0.7) | >.999 |
| No growth or mixed flora without specific organism identified | 35 (87.5) | 120 (85.1) | <.001 |
| Received antibiotics preprocedurea,b | 32 (36.4) | 150 (99.3) | <.001 |
| Cephalexin | 8 (25.0) | 114 (76.0) | <.001 |
| Cefazolin | 10 (31.3) | 14 (9.3) | .604 |
| Ciprofloxacin | 6 (18.9) | 7 (4.7) | .473 |
| Levofloxacin | 0 | 7 (4.7) | .049 |
| Cefdinir | 0 | 4 (2.7) | <.001 |
| Cefepime | 3 (9.4) | 4 (2.7) | .710 |
| Amoxicillin | 0 | 4 (2.7) | .161 |
| Vancomycin | 1 (3.1) | 4 (2.7) | .654 |
| Tobramycin | 0 | 4 (2.7) | .300 |
| Gentamicin | 3 (9.4) | 2 (1.3) | .360 |
| Otherc | 5 (15.6) | 7 (4.7) | .764 |
| TMP-SMX for prophylaxis at time of stent removald | 81 (92.0) | 135 (89.4) | .651 |
| Received antibiotics postprocedure | 10 (11) | 29 (19) | .148 |
| Duration of antibiotics postprocedure, d | 4 (2–15) | 4 (2–7) | … |
Data are presented as median (IQR) or No. (%).
Abbreviations: TMP-SMX: trimethoprim-sulfamethoxazole; WBC, white blood cell.
aNot mutually exclusive.
bDoes not include TMP-SMX for prophylaxis.
cAmoxicillin-clavulanate, ampicillin, ceftazidime-avibactam, ceftriaxone, clindamycin, daptomycin, ertapenem, linezolid, meropenem, metronidazole, piperacillin-tazobactam.
dTMP-SMX dosed at 80–400 mg daily (renally adjusted as needed).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
